Lessons For Biosimilar And Biologic Antitrust Litigation
The future of pharmaceutical antitrust litigation will likely focus in large part on biologics and biosimilars. Cases involving the delayed market entry of generic pharmaceuticals have traditionally focused on small-molecule generic...To view the full article, register now.
Already a subscriber? Click here to view full article